Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Feature|Articles|November 5, 2026
TroFuse-005, KEYNOTE-C93, and ADC Data Headline Key Gynecologic Cancer Findings from ESMO 2026
Author(s)OncLive Staff
Fact checked by: Riley Kandel
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Advertisement
Advertisement
Sacituzumab tirumotecan (sac-TMT; SKB264/MK-2870) in the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 trial (NCT06132958) and first-line pembrolizumab (Keytruda) in the phase 3 KEYNOTE-C93/GOG-3064/ENGOT-en15 trial (NCT05173987) were among the most closely watched gynecologic cancer data and trends presented at the
Related to this article
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Sac-TMT extended survival and improved response rates vs chemotherapy in endometrial cancer that had progressed after chemotherapy and immunotherapy.
Single-agent pembrolizumab extended progression-free survival vs carboplatin and paclitaxel in mismatch repair–deficient endometrial cancer.
Adding pembrolizumab to adjuvant radiation did not meet prespecified superiority criteria in patients with stage I/II high-intermediate–risk dMMR endometrioid endometrial cancer in the phase 3 NRG-GY020 trial.
Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Advertisement
Advertisement